Long-term efficacy of imatinib for treatment of metastatic GIST Shreyaskumar Patel Review Article 17 March 2013 Pages: 277 - 286
CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis Zhiyu ZengYanqiong LiuXue Qin Review Article 28 May 2013 Pages: 287 - 303
Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis Zhi PengQianqian WangLin Shen Original Article 22 May 2013 Pages: 305 - 314
Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy Cui ChenFenghua WangYuhong Li Original Article 28 May 2013 Pages: 315 - 322
Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy Pei-Jian PengXue-Qing OuZhong Lin Original Article 01 June 2013 Pages: 323 - 328
Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines Linda SoomanSimon EkmanJoachim Gullbo Original Article 05 June 2013 Pages: 329 - 340
Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib Peng HeGang Li Original Article Open access 08 June 2013 Pages: 341 - 348
The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis Nimita DaveGary A. GudelskyPankaj B. Desai Original Article 09 June 2013 Pages: 349 - 357
Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study R. P. JonesP. SuttonN. R. Kitteringham Original Article 12 June 2013 Pages: 359 - 368
Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments Jennifer L. PauleyJohn C. PanettaMary V. Relling Original Article Open access 13 June 2013 Pages: 369 - 378
A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers Carlo L. BelloEvan SmithCho-Ming Loi Original Article 13 June 2013 Pages: 379 - 385
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study Edward M. WolinKe HuKarina Hermosillo Resendiz Original Article Open access 14 June 2013 Pages: 387 - 395
Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer David TougeronUlrich CortesLucie Karayan-Tapon Original Article 14 June 2013 Pages: 397 - 403
Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration–effect relationship support clinical dose and regimen selection Hong XiangArthur E. Reyes IILisa A. Damico-Beyer Original Article 16 June 2013 Pages: 405 - 415
Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate Ruth DuncanYee-Nee Sat-KlopschEdward A. Sausville Original Article Open access 25 June 2013 Pages: 417 - 427
Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer Maged MansourCynthia Mourad Original Article 26 June 2013 Pages: 429 - 435
A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer Ibrahim YildizFaruk TasAdnan Aydiner Original Article 26 June 2013 Pages: 437 - 444
Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study Masato KarayamaNaoki InuiKingo Chida Original Article 27 June 2013 Pages: 445 - 452
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab Matthew D. HellmannJamie E. ChaftPaul K. Paik Original Article 28 June 2013 Pages: 453 - 461
A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis Masafumi IkedaTakuji OkusakaYasuaki Arai Original Article 29 June 2013 Pages: 463 - 470
A predictive pharmacokinetic–pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination Nadia TerranovaMassimiliano GermaniPaolo Magni Original Article Open access 29 June 2013 Pages: 471 - 482
DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity Enrica RumiatoElisa BoldrinDaniela Saggioro Short Communication 13 June 2013 Pages: 483 - 488
Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not) Salvatore Maria CorselloRoberto SalvatoriFrancesco Torino Letter to the Editor 19 June 2013 Pages: 489 - 490
Erratum to: Differential toxicity biomarkers for irinotecan- and oxaliplatin- containing chemotherapy in colorectal cancer Lucía CortejosoMaría I. GarcíaLuis A. Lόpez-Fernández Erratum 28 June 2013 Pages: 491 - 491